Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors
Authors
Keywords
-
Journal
Future Oncology
Volume -, Issue -, Pages -
Publisher
Future Medicine Ltd
Online
2019-05-14
DOI
10.2217/fon-2018-0934
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Sunitinib in patients with pancreatic neuroendocrine tumors: update of safety data
- (2019) Juan W Valle et al. Future Oncology
- Sunitinib shrinks NET-G3 pancreatic neuroendocrine neoplasms
- (2018) Yuki Mizuno et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Efficacy and Safety of Sunitinib in Patients With Well-Differentiated Pancreatic Neuroendocrine Tumours
- (2018) Eric Raymond et al. NEUROENDOCRINOLOGY
- Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study
- (2018) Maria Rinzivillo et al. PANCREATOLOGY
- Impact of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) single nucleotide polymorphisms on outcome in gastroenteropancreatic neuroendocrine neoplasms
- (2018) Rossana Berardi et al. PLoS One
- Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis
- (2018) Daniel J. George et al. CLINICAL CANCER RESEARCH
- Biomarkers and polymorphisms in pancreatic neuroendocrine tumors treated with sunitinib
- (2018) Paula Jiménez-Fonseca et al. Oncotarget
- Interleukins as new prognostic genetic biomarkers in non-small cell lung cancer
- (2017) Cristina Pérez-Ramírez et al. SURGICAL ONCOLOGY-OXFORD
- Effects of VEGF and VEGFR polymorphisms on the outcome of patients with metastatic renal cell carcinoma treated with sunitinib: a systematic review and meta-analysis
- (2017) Chenkui Miao et al. Oncotarget
- Validation of VEGFR1 rs9582036 as predictive biomarker in metastatic clear-cell renal cell carcinoma patients treated with sunitinib
- (2016) Benoit Beuselinck et al. BJU INTERNATIONAL
- Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma
- (2016) Camillo Porta et al. EUROPEAN UROLOGY
- A decade of pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell cancer: a systematic review
- (2016) Meta H. M. Diekstra et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Evaluation of polymorphisms in angiogenesis-related genes as predictive and prognostic markers for sunitinib-treated metastatic renal cell carcinoma patients
- (2016) Juana Dornbusch et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Identification of sequence polymorphisms in the displacement loop region of mitochondrial DNA as a risk factor for gastroenteropancreatic neuroendocrine neoplasm
- (2016) Li-Mian Er et al. JOURNAL OF CLINICAL LABORATORY ANALYSIS
- Influence of VEGFR single nucleotide polymorphisms on the efficacy of sunitinib therapy against renal cell carcinoma
- (2016) Rui Liu et al. Oncology Letters
- Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma
- (2016) Maristella Bianconi et al. Oncotarget
- Common germline variants within the CDKN2A/2B region affect risk of pancreatic neuroendocrine tumors
- (2016) Daniele Campa et al. Scientific Reports
- Genetic polymorphisms ofinterleukin 1βgene and sporadic pancreatic neuroendocrine tumors susceptibility
- (2016) Dimitrios Karakaxas et al. World Journal of Gastrointestinal Oncology
- Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)
- (2015) E. Grande et al. ANNALS OF ONCOLOGY
- CYP3A5 and ABCB1 Polymorphisms as Predictors for Sunitinib Outcome in Metastatic Renal Cell Carcinoma
- (2015) Meta H.M. Diekstra et al. EUROPEAN UROLOGY
- Pharmacogenomic biomarkers for personalized cancer treatment
- (2015) C. Rodríguez-Antona et al. JOURNAL OF INTERNAL MEDICINE
- Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib
- (2014) Benoit Beuselinck et al. ACTA ONCOLOGICA
- VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib – a multicentric retrospective analysis
- (2013) Benoit Beuselinck et al. ACTA ONCOLOGICA
- Pancreatic well-differentiated neuroendocrine neoplasms (pWDNENs): what place for everolimus and sunitinib derived from ESMO clinical practice guidelines in the therapeutic algorithm?
- (2013) S. Pusceddu et al. ANNALS OF ONCOLOGY
- VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib
- (2013) M Scartozzi et al. BRITISH JOURNAL OF CANCER
- Emerging therapies and latest development in the treatment of unresectable pancreatic neuroendocrine tumors: an update for clinicians
- (2013) Jaya Sharma et al. Therapeutic Advances in Gastroenterology
- VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials
- (2012) Diether Lambrechts et al. LANCET ONCOLOGY
- Interleukin 1β Gene Single-Nucleotide Polymorphisms and Susceptibility to Pancreatic Neuroendocrine Tumors
- (2011) Maja Cigrovski Berković et al. DNA AND CELL BIOLOGY
- The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemotherapy in patients with metastatic colorectal cancer
- (2011) Torben Frøstrup Hansen et al. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
- Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study
- (2011) Jesus Garcia-Donas et al. LANCET ONCOLOGY
- Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
- (2011) Eric Raymond et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival
- (2008) T. R. Halfdanarson et al. ANNALS OF ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started